
浏览全部资源
扫码关注微信
1.550025 贵阳,贵州医科大学公共卫生学院
2.400038 重庆,陆军军医大学(第三军医大学)军事预防医学系环境卫生学教研室
[周紫垣,E-mail: ziyuanzhou@tmmu.edu.cn ZHOU Ziyuan, E-mail: ziyuanzhou@tmmu.edu.cn
[杨光红,E-mail: 280446859@qq.com YANG Guanghong, E-mail: 280446859@qq.com
收稿:2021-03-30,
修回:2021-04-13,
纸质出版:2021-10-15
移动端阅览
杨建英, 王灵巧, 陈维艳, 等. 二甲双胍通过PP2A/AKT通路诱导结直肠癌细胞衰老[J]. 第三军医大学学报, 2021,43(19):1860-1869.
Jianying YANG, Lingqiao WANG, Weiyan CHEN, et al. Metformin induces senescence of colorectal cancer cells through PP2A/AKT pathway[J]. Journal of Third Military Medical University, 2021, 43(19): 1860-1869.
杨建英, 王灵巧, 陈维艳, 等. 二甲双胍通过PP2A/AKT通路诱导结直肠癌细胞衰老[J]. 第三军医大学学报, 2021,43(19):1860-1869. DOI: 10.16016/j.1000-5404.202103252.
Jianying YANG, Lingqiao WANG, Weiyan CHEN, et al. Metformin induces senescence of colorectal cancer cells through PP2A/AKT pathway[J]. Journal of Third Military Medical University, 2021, 43(19): 1860-1869. DOI: 10.16016/j.1000-5404.202103252.
目的
2
明确二甲双胍(1,1-二甲基双胍盐酸盐,Met)是否通过诱导细胞衰老抑制结直肠癌细胞增殖,并初步探讨其诱导细胞衰老的机制。
方法
2
以不同浓度Met(0、2.5、5.0、10.0、20.0、40.0 mmol/L)处理结直肠癌LOVO、SW480细胞,采用CCK-8检测细胞活力,流式细胞仪检测细胞凋亡和周期。根据凋亡结果将实验分为对照组、5.0 mmol/L Met组(
n
=3),采用EdU和克隆形成实验检测细胞增殖,衰老相关β-半乳糖苷酶(SA-β-gal)染色检测细胞衰老代谢,ELASA检测蛋白磷酸酶2A(protein phosphatase 2A
PP2A)酶活性,Western blot检测蛋白表达。用PP2A抑制剂LB-100联合Met处理细胞并分为对照组、Met组、Met+LB-100组、LB-100组(
n
=3),再次用CCK-8和克隆形成实验检测细胞增殖,SA-β-ga1染色检测细胞衰老情况。
结果
2
Met以浓度和时间依赖方式显著抑制结直肠癌细胞LOVO、SW480增殖(
P
<
0.05);低浓度(≤5.0 mmol/L)Met作用下,细胞无明显凋亡,但有明显增殖抑制和G
0
/G
1
期阻滞;细胞呈大而扁平、空泡化增多的典型衰老样态,衰老标志SA-β-gal阳性细胞明显增加;此时,PP2A蛋白表达无改变,但磷酸化水平显著降低,PP2A酶活性则显著升高(
P
<
0.05),其下游AKT蛋白磷酸化水平降低,衰老相关蛋白P53、P21等表达明显增加。PP2A抑制剂LB-100联合Met处理后,可明显逆转Met对细胞增殖的抑制,并延缓Met诱导的细胞衰老。
结论
2
低浓度Met可通过PP2A/AKT通路诱导细胞衰老从而抑制结直肠癌细胞增殖。
Objective
2
To determine whether metformin(Met) inhibits the proliferation of colorectal cancer cells by inducing cell senescence
and to preliminarily explore the underlying mechanism.
Methods
2
LOVO and SW480 colorectal cancer cells were treated with different concentrations of Met(0
2.5
5.0
10.0
20.0 and 40.0 mmol/L). The cell viability was detected by CCK-8 assay
and apoptosis and cell cycle were detected by flow cytometry. According to the results of apoptosis
differences between control group (0 mmol/L) and 5.0 mmol/L Met group(
n
=3) were compared in following experiments. Cell proliferation was detected by CCK-8 assay
EdU assay
and clone formation assay
senescence metabolism was detected by senescence-associated β-galactosidase(SA-β-gal)
staining
protein phosphatase 2A(PP2A) enzyme activity was measured with ELASA
and protein expression was detected with Western blotting. PP2A inhibitor LB-100 was used to treat the cells alone or combined with Met
and then the cells were divided into control group
Met group
Met+LB-100 group
and LB-100 group(
n
=3). Above experiments were performed again.
Results
2
Met treatment significantly inhibited LOVO and SW480 cells proliferation in a concentration- and time-dependent manner(
P
<
0.05). Under the treatment of low concentration(≤5.0 mmol/L) of Met
the cells presented no obvious apoptosis
but were obviously inhibited for proliferation and arrested at G
0
/G
1
phase. The cells displayed a typical senescence-like morphology of large
flat and vacuolated
and the number of SA-β-gal positive cells was increased significantly. For PP2A
total protein expression showed no change
but phosphorylation level decreased obviously and PP2A activity increased statistically(
P
<
0.05)
in the meantime
the phosphorylation level of downstream AKT protein decreased and senescence-related proteins p53 and P21 increased significantly. Treatment by PP2A inhibitor LB-100 combined with Met significantly reversed the inhibition of Met on cell proliferation and delayed Met-induced cell senescence.
Conclusion
2
Low concentration of Met can induce cell senescence through PP2A/AKT pathway and then inhibit the proliferation of colorectal cancer cells.
BRAY F, FERLAY J, SOERJOMATARAM I, et al . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J ] . CA Cancer J Clin, 2018, 68(6): 394-424. DOI:10.3322/caac.21492.
WU C, LI M, MENG H, et al . Analysis of status and countermeasures of cancer incidence and mortality in China[J ] . Sci China Life Sci, 2019, 62(5): 640-647. DOI:10.1007/s11427-018-9461-5.
WYLD L, BELLANTUONO I, TCHKONIA T, et al . Senescence and cancer: A review of clinical implications of senescence and senotherapies[J ] . Cancers(Basel), 2020, 12(8). DOI:10. 3390/cancers12082134.16/j.canlet. 2017. 09. 027.
ZHOU D, BORSA M, SIMON A K. Hallmarks and detection techniques of cellular senescence and cellular ageing in immune cells[J]. Aging Cell, 2021, 20(2): e13316. DOI:10.1111/acel.13316.
OU H L, SCHUMACHER B. DNA damage responses and p53 in the aging process[J]. Blood, 2018, 131(5): 488-495. DOI:10.1182/blood-2017-07-746396.
EWALD J A, DESOTELLE J A,WILDING G, et al . Therapy-induced senescence in cancer[J ] . J Natl Cancer Inst, 2010, 102(20): 1536-1546. DOI:10.1093/jnci/djq364.
XUE W, ZENDER L, MIETHING C, et al . Senescence and tumour clearance is triggere d by p53 restoration in murine liver carcinomas[J ] . Nature, 2007, 445(7128): 656-660. DOI:10.1038/nature05529.
CAIRNEY C J, BILSLAND A E, EVANS T R, et al . Cancer cell senescence: a new frontier in drug development[J ] . Drug Discov Today, 2012, 17(5/6): 269-276. DOI:10.1016/j.drudis.2012.01.019.
MALLIK R, CHOWDHURY T A. Metformin in cancer[J]. Diabetes Res Clin Pract, 2018, 143: 409-419. DOI:10.1016/j.diabres.2018.05.023.
SAFE S, NAIR V, KARKI K. Metformin-induced anticancer activities: recent insights[J]. Biol Chem, 2018, 399(4): 321-335. DOI:10.1515/hsz-2017-0271.
KAMARUDIN M N A, SARKER M M R, ZHOU J R, et al . Metformin in colorectal cancer: molecular mechanism, preclinical and clinical aspects[J ] . J Exp Clin Cancer Res, 2019, 38(1): 491. DOI:10.1186/s13046-019-1495-2.
XIA C, YANG F, HE Z, et al . iTRAQ-based quantitative proteomic analysis of the inhibition of cervical cancer cell invasion and migration by metformin[J ] . Biomed Pharmacother, 2020, 123: 109762. DOI:10.1016/j.biopha.2019.109762.
LI P, ZHAO M, PARRIS A B, et al . p53 is required for metformin-induced growth inhibition, senescence and apoptosis in breast cancer cells[J ] . Biochem Biophys Res Commun, 2015, 464(4): 1267-1274. DOI:10.1016/j.bbrc.2015.07.117.
WILLIAMS C C, SINGLETON B A, LLOPIS S D, et al . Metformin induces a senescence-associated gene signature in breast cancer cells[J ] . J Health Care Poor Underserved, 2013, 24(1 suppl): 93-103. DOI:10.1353/hpu.2013.0044.
YI G, HE Z, ZHOU X, et al . Low concentration of metformin induces a p53-dependent senescence in hepatoma cells via activation of the AMPK pathway[J ] . Int J Oncol, 2013, 43(5): 1503-1510. DOI:10.3892/ijo.2013.2077..
ZHOU X, CHEN J, CHEN L, et al . Negative regulation of Sirtuin 1 by AMP-activated protein kinase promotes metformin-induced senescence in hepatocellular carcinoma xenografts[J ] . Cancer Lett, 2017, 411: 1-11. DOI:10.1016/j.canlet.2017.09.027.
ABU E, STRASSBURGER W, QAISER T, et al . Differences in p53 status significantly influence the cellular response and cell survival to 1, 25-dihydroxyvitamin D3-metformin cotreatment in colorectal cancer cell s[J ] . Mol Carcinog, 2017, 56(11): 2486-2498. DOI: 10. 1002/mc. 22696.
HOSONO K, ENDO H, TAKAHASHI H, et al . Metformin suppresses azoxymethane-induced colorectal aberrant crypt foci by activating AMP-activated protein kinase[J ] . Mol Carcinog, 2010, 49(7): 662-671. DOI: 10.1002/mc.20637.
MOGAVERO A, MAIORANA M V, ZANUTTO S, et al . Metformin transiently inhibits colorectal cancer cell proliferation as a result of either AMPK activation or increased ROS production[J ] . Sci Rep, 2017, 7(1): 15992. DOI:10.1038/s41598-017-16149-z.
FOWLE H, ZHAO Z, GRAÑA X. PP2A holoenzymes, substrate specificity driving cellular functions and deregulation in cancer[J]. Adv Cancer Res, 2019, 144: 55-93. DOI:10.1016/bs.acr.2019.03.009.
吴燕芳. PP2A复合物在Ras引起的细胞衰老中的功能初探[D]. 江苏大学, 2017.
WU Y F. The preliminary study on the function of PP2A complex in cellular senescence induced by Ras[D]. Jiangsu University, 2017.
MANNAVA S, OMILIAN A R, WAWRZYNIAK J A, et al . PP2A-B56α controls oncogene-induced senescence in normal and tumor human mela nocytic cells[J ] . Oncogene, 2012, 31(12): 1484-1492. DOI:10.1038/onc.2011.339.
O'CONNOR C M, PERL A, LEONARD D, et al . Therapeutic targeting of PP2A[J ] . Int J Biochem Cell Biol, 2018, 96: 182-193. DOI:10.1016/j.biocel.2017.10.008.
CRISTÓBAL I, GARCIA-ORTI L, CIRAUQUI C, et al . PP2A impaired activity is a common event in acute myeloid leukemia and its activation by forskolin has a potent anti-leukemic effect[J ] . Leukemia, 2011, 25(4): 606-614. DOI:10.1038/leu.2010.294.
XIONG Y, JING X P, ZHOU X W, et al . Zinc induces protein phosphatase 2A inactivation and tau hyperphosphorylation through Src dependent PP2A(tyrosine 307) phosphorylation[J ] . Neurobiol Aging, 2013, 34(3): 745-756. DOI:10.1016/j.neurobiolaging.2012.07.003.
CRISTÓBAL I, RINCÓN R, MANSO R, et al . Hyperphosphorylation of PP2A in colorectal cancer and the potential therapeutic value showed by its forskolin-induced dephosphorylation and activation[J ] . Biochim Biophys Acta, 2014, 1842(9): 1823-1829. DOI:10.1016/j.bbadis.2014.06.032.
KAWASHIMA I, KIRITO K. Metformin inhibits JAK2V617F activity in MPN cells by activating AMPK and PP2A complexes containing the B56alpha subunit[J]. Exp Hematol, 2016, 44(12): 1156-1165. DOI:10.1016/j.exphem.2016.08.005.
0
浏览量
0
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010802024621